[Therapeutic effect of capsule xinganbao on schistosomal hepatocirrhosis].

A total of 118 patients with schistosomal hepatocirrhosis were divided into an experiment group (62 cases) and a control group (56 cases), and the former received capsule Xinganbao and the latter received conventional medicine for 6 months. The reductions of serum HA, LN and PCIII were more notable in the experiment group than in the control group (P < 0.05). The clinical symptoms, physical signs, and liver function improved in both groups, and there were no significant differences between two groups. In conclusions, capsule Xinganbao has a good effect on hepatic fibrosis.